Tag

Mrna 4157

All articles tagged with #mrna 4157

investing1 hour ago•21 min saved

Moderna’s Cancer Vaccine Breakthrough Triggers Massive Rally, Then Profit-Taking

Moderna’s personalized cancer vaccine mRNA-4157 (intismeran autogene) paired with Merck’s Keytruda hit key Phase 3 melanoma endpoints, delivering a 49% reduction in recurrence or death versus Keytruda alone and sparking a 177% one‑day stock surge before shares retraced about 20% as investors took profits; Moderna’s pipeline spans nine Phase 2/3 studies across melanoma, NSCLC, bladder and kidney cancers, despite a $950 million settlement and a norovirus program setback, while Merck’s KEYTRUDA franchise remains a critical driver for oncology growth.

via 24/7 Wall St.|

#cancer-vaccine #investing #melanoma

medical-research2 years ago•47 min saved

Moderna and Merck's Combined Cancer Therapy Shows Promising Results in Melanoma Trial

Moderna and Merck have announced follow-up data from a Phase 2b study showing that mRNA-4157 (V940) in combination with KEYTRUDA demonstrated continued improvement in recurrence-free survival and distant metastasis-free survival in patients with high-risk stage III/IV melanoma following complete resection. At a median planned follow-up of approximately three years, the combination therapy reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone. The companies have initiated Phase 3 studies in the adjuvant setting for melanoma and non-small cell lung cancer and plan to expand to additional tumor types.

via Moderna Investor Relations|

#keytruda #medical-research #melanoma

healthcare3 years ago•1 min saved

mRNA cancer vaccine shows promise in reducing melanoma relapse and death.

Merck and Moderna presented detailed mid-stage results for a combination therapy containing vaccine maker’s personalized cancer shot mRNA-4157 and pharma giant’s blockbuster cancer therapy Keytruda at a medical event on Sunday. The novel therapeutic regimen cut the risk of recurrence or death by 44%, leading to a statistically significant and clinically meaningful improvement in recurrence-free survival (RFS) compared to Keytruda alone in patients with skin cancer, melanoma. In 2023, Merck and Moderna expect to begin a Phase 3 trial for the combination therapy in adjuvant melanoma before expanding studies to additional cancer types, such as non-small cell lung cancer.

via Seeking Alpha|

#cancer #healthcare #keytruda